RadOnc on the Run

At the 2026 ASCO Genitourinary Cancers Symposium, RadOnc on the Run host Brandon Mancini, MD, MBA, FACRO, reviewed several key presentations on the growing roles that radiotherapeutic modalities could play in the management of genitourinary malignancies. He spoke in San Francisco, CA, to highlight oral abstracts and poster sessions exploring the intersection between radiation oncology and prostate cancer, kidney cancer, and other patient populations.Among numerous abstracts, Mancini, director at Bold Advanced Medical Future Health, clinical associate professor in the Department of Radiology at Michigan State University College of Human Medicine, and editor at large for RadOnc Review, a supplement of the journal ONCOLOGY®, highlighted the following:How Do Pre-Visit Educational Videos Impact Prostate Cancer Radiation Consultations?One presentation explored whether provider-developed educational videos could minimize the amount of time that radiation oncology clinicians, residents, and nurses dedicate to patients for prostate cancer consults, thereby boosting clinical efficiency. Data showed that administering videos alone without changing provider approaches may not be sufficient to improve clinical efficiency, although educational videos may give patients more resources to develop questions before a clinical visit. Findings from this study, Mancini said, may prompt clinicians to reconsider how to prepare patients more effectively for their consults.How Safe is Immunotherapy Plus Radiation in High-Risk Prostate Cancer?As part of another presentation, investigators of a phase 2 trial (NCT05568550) evaluated the safety of pembrolizumab (Keytruda) plus radiotherapy and androgen deprivation therapy (ADT) with or without olaparib (Lynparza) among those with high-risk localized prostate cancer. The investigators noted that pembrolizumab plus radiation/ADT was feasible and typically tolerable, and that adding olaparib to this regimen did not increase the incidence of high-grade adverse effects, although low-grade urinary toxicities were more common. Mancini said that these results may warrant further investigation of pembrolizumab-based treatment to determine whether patient outcomes can improve in the long term.Can LLMs Help Grade Radiation-Related Toxicities?In another study presented at the meeting, investigators evaluated the ability of large language models (LLMs) to extract and grade toxicities from clinical notes and patient-reported outcomes among those who underwent radiotherapy for prostate cancer in a phase 2 trial (NCT02874014). Overall, the investigator’s ensemble model achieved strong performance metrics, supporting the conclusion that LLMs could feasibly extract and grade toxicity in this population. Besides supporting LLMs as potential assistants in one’s workflow, Mancini described how this study reflects the need to capture “every last ounce” of data from patients in radiation oncology practice.References Martin SA, Amin SA, Strudthoff E, Baine M. Impact of pre-visit educational videos on clinic efficiency for prostate cancer radiation oncology consultations. J Clin Oncol. 2026;44(suppl 7):332. doi:10.1200/JCO.2026.44.7_suppl.332 Myint ZW, Yan D, Strup S, et al. Interim safety analysis of a randomized phase II trial comparing pembrolizumab with radiation versus pembrolizumab, olaparib, and radiation in localized high risk prostate cancer. J Clin Oncol. 2026;44(suppl 7):362. doi:10.1200/JCO.2026.44.7_suppl.362 Wilson R, Mastroleo F, Osorio MB, et al. Using large language models for grading CTCAE toxicity after radiation therapy for prostate cancer. J Clin Oncol. 2026;44(suppl 7):357. doi:10.1200/JCO.2026.44.7_suppl.357

As part of honoring National Cancer Prevention Month in February, RadOnc on the Run host Brandon Mancini MD, MBA, spoke with Jenni Beamer about a broad range of topics dedicated to proactively treating patients who are at risk of developing cancer. Beamer, senior executive director for the state of Michigan at the American Cancer Society (ACS), emphasized the importance of having a designated month to educate the public regarding lifestyle choices, regular screenings, and other modifiable risk factors that may influence the likelihood of a cancer diagnosis. Regarding specific campaigns focused on cancer prevention, she brought attention to ACS CancerRisk360, a free digital tool that provides a comprehensive cancer risk evaluation based on key areas like genetic risk, family history, screening adherence, and daily life factors. Mancini highlighted how the challenges surrounding cancer prevention have evolved as environmental and exposure-related risk factors have transformed over time. For example, while rates of smoking—a common risk factor for lung cancer—have decreased, vaping has appeared to pick up, which may cause long-term complications in terms of cancer risk. Beamer and colleagues stay up to date on strategies for managing these modifiable risk factors via national roundtables, which also cover areas like breast cancer screening and HPV vaccination.“Just yesterday, we reported out a 27% decline in cervical cancer incidence rates that are directly related to the implementation of the vaccine. That just gives me chills to know,” Beamer stated. “That’s why my 3 kids have that cancer vaccine. Progress is happening, and it’s in the stories of the everyday people that want to make a difference. I’m so motivated and proud of everyone’s collective energy and work around this.”Mancini is director at Bold Advanced Medical Future (BAMF) Health, clinical associate professor in the Department of Radiology at Michigan State University College of Human Medicine, and editor-at-large for the RadOnc Review, a supplement of the journal ONCOLOGY®.ReferenceDeclines in cervical cancer incidence in U.S. varied substantially by state, aligning with HPV vaccination rates, new ACS study finds. News release. American Cancer Society. February 23, 2026. Accessed February 25, 2026. https://tinyurl.com/57rykdvk

At the 2026 American College of Radiation Oncologists (ACRO) Summit, host Brandon Mancini, MD, MBA, FACRO, sat down with Brian Lally, MD, FACRO, to chat about the latest happenings at the meeting. Throughout their discussion, they emphasized advocating for the radiation oncology field and networking with others to spread the potential impact of radiotherapy.Lally began with an overview of his involvement with ACRO, describing his participation in the planning committee for the annual summits as well as his previous work in finance and operations. He and Mancini stressed the intimate nature of meetings like the ACRO Summit, where radiation oncologists can network and form long-lasting professional relationships and personal connections with one another.Regarding other notable initiatives in the field, Lally brought attention to the efforts of Jessica Schuster, MD, FACRO, who serves as the editor-in-chief of Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE), an ACRO-based publication highlighting new advancements in radiation oncology. He also discussed a new accreditation program that serves as a joint venture between ACRO, the American College of Radiology (ACR), and the Radiosurgery Society (RSS), which may contribute to further growth in the field.“Advocacy is such a critical component of ACRO. It is critical that we advocate for the field and represent the college and our members in DC so that we can stay in our clinics and treat our patients,” Lally stated. “You’re not going to see a direct return on the investment you put into those programs—ACR, ACRO, and the American Society for Radiation Oncology [ASTRO]—but it’s critical that you be part of them. It’s critical that you participate.”Mancini is director at Bold Advanced Medical Future Health, clinical associate professor in the Department of Radiology at Michigan State University College of Human Medicine, and editor at large for the RadOncReview, a supplement of the journal ONCOLOGY®. Lally is president-elect of ACRO and an associate professor and vice-chair for Operations in the Department of Radiation Oncology and Hollings Cancer Center Medical University of South Carolina.

In observance of Cervical Cancer Awareness Month in January, host Brandon Mancini, MD, MBA, FACRO, convened with Melissa Wylie Brackmann, MD, to highlight various advancements in cervical cancer prevention and treatment as well as critical takeaways for elevating the quality of patient care. The experts touched upon advancements in screening, preventative vaccination, surgical and systemic modalities, and other key areas in the field.Brackmann began by noting how cervical cancer may take a long time to develop, and that detecting high-risk pre-cancers through screening may help prevent the formation of more advanced diseases. Given cervical cancer’s association with HPV infections, the discussion also focused on the role that HPV vaccination can play in limiting the risk of cervical cancer.According to Brackmann, other potential advancements in the cervical cancer space pertain to targeted therapies, which include immunotherapeutic agents like pembrolizumab (Keytruda) and antibody drug conjugates like tisotumab vedotin-tftv (Tivdak). The experts also spoke about considerations for counseling patients on the safety of radiation and surgical modalities like hysterectomy while balancing realism with hope when developing a personalized treatment plan. Brackmann concluded by emphasizing the importance of patients undergoing screening for potential disease and seeking resources related to other preventative strategies.“There is a tremendous amount of hope, in the community and amongst [gynecologic] oncologists, for this cancer to be better treated and better managed,” Brackmann stated during the discussion. “[It] is often curable in early stages [while] having less long-term [adverse] effects from our chemotherapies, our radiations, and our surgeries.”Mancini is director at Bold Advanced Medical Future Health, clinical associate professor in the Department of Radiology at Michigan State University College of Human Medicine, and editor-at-large for the RadOnc Review, a supplement of the journal ONCOLOGY®. Brackmann is an assistant professor of Gynecologic Oncology at the University of Michigan Medical School.

As part of ushering in a new podcast series on CancerNetwork®, Brandon Mancini, MD, MBA, FACRO, introduced himself as the host of RadOnc on the Run, a program dedicated to discussing critical advances and considerations in radiation oncology care and research. He outlined the podcast’s objective of serving as an educational resource among radiation oncologists in the field, describing aims such as reviewing the latest data to emerge from key oncology conferences and meetings, as well as strategies for collaborating with members of a multidisciplinary team. Additionally, the program looks to share ideas for safely and efficiently administering radiation to patients by touching upon topics like billing, policy, and mitigating potential adverse effects during treatment.Mancini first discussed how his background and prior work led to his current roles in the field. He is currently the director at BAMF Health, clinical associate professor in the Department of Radiology at Michigan State University College of Human Medicine, and editor-at-large for The RadOnc Review, a supplement of the journal ONCOLOGY®.  On top of the new podcast, Mancini emphasized the RadOnc Review as a new resource that may fill an informational gap in the radiation oncology space. The supplement, which will be PubMed-indexed under the journal ONCOLOGY and published on a quarterly basis, is currently accepting all major manuscript types.As part of RadOnc on the Run, Mancini detailed the goal of keeping listeners up to date with techniques, challenges, and other developments regarding the radiotherapeutic management of cancer. Emphasizing expert-led, high-level insights, the podcast will feature perspectives from specialists in surgical oncology, gynecologic oncology, patient advocacy, and other disciplines to explore how widely applicable radiation therapy can be. From covering benign conditions like osteoarthritis to discussing novel modalities such as MRI-guided radiation therapy, RadOnc on the Run will deliver comprehensive conversations on the most salient topics in radiation oncology.